XARELTO ® (rivaroxaban) Significantly Reduced Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation in Large, Real-World Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs)

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news

Related Links:

Conditions:   Stroke;   Atrial Fibrillation Intervention:   Device: Smartphone ECG Sponsors:   Sarawak Heart Centre;   Ministry of Health, Malaysia Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This article reviews the evidence base and recommendations for medical management for secondary stroke prevention. RECENT FINDINGS Recent developments for secondary stroke prevention include evidence to support the use of short-term dual antiplatelet therapy after minor stroke and transient ischemic attack, direct oral anticoagulants for nonvalvular atrial fibrillation, reversal agents for direct oral anticoagulant–associated hemorrhage, and aspirin rather than presumptive anticoagulation with a direct oral anticoagulant for embolic stroke of undetermined source. SUMMARY Most strokes are preventable. The mainst...
Source: CONTINUUM: Lifelong Learning in Neurology - Category: Neurology Tags: REVIEW ARTICLES Source Type: research
ConclusionsStroke or stroke-like syndrome of infectious origin can be observed in an important proportion of case presenting with sensory-motor deficit of unknown origin; their accurate diagnosis has a considerable impact in terms of treatment choices and outcome.
Source: Infection - Category: Infectious Diseases Source Type: research
ConclusionThis propensity score analysis demonstrated that the EVT patients with acute ICAD-related MCA M1 occlusion had similar angiographic and clinical outcomes compared to those with M1 embolism on a  similar baseline condition.
Source: Klinische Neuroradiologie - Category: Radiology Source Type: research
ConclusionIn ENSURE-AF, thromboembolic events were rare and absolute bleeding event rates were higher with concomitant APT. These findings may be relevant for AF-patients considered for dual therapy; even for a short treatment duration of 1  month.
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Source: Neurological Sciences - Category: Neurology Source Type: research
ConclusionIn this real world, population ‐based cohort of patients with newly diagnosed AF, we found a lower than expected rate of OAC prescription within 3 months of diagnosis but an encouraging increase in OAC purchasing over time. Use of NOACs has risen exponentially in only a few years, accounting for a greater pool of AF patients be ing prescribed an OAC.This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - Category: Cardiology Authors: Tags: ORIGINAL ARTICLE Source Type: research
AbstractIntroductionDabigatran is effective and widely used to prevent ischemic stroke and systemic embolism (SE) in patients with atrial fibrillation (AF). Chronic kidney disease (CKD) also has implications for choice of any medications, as it alters pharmacokinetic parameters of drugs.AimTo evaluate trough plasma dabigatran concentration (DTPC) and to analyse potential factors affecting these values in patients with AF and CKD.MethodsPatients with AF and stage 3 CKD were treated with dabigatran 110  mg or 150 mg have been included in the study and allocated into D110 or D150 group. DTPC was evaluated with high-...
Source: High Blood Pressure and Cardiovascular Prevention - Category: Cardiology Source Type: research
This study included 1962 patients who underwent transesophageal echocardiographic examination (TEE) prior to cardioversion or ablation in the years 2014-2018 in three cardiac centers. RESULTS: More than a quarter of AF patients had decreased eGFR (
Source: Cardiology Journal - Category: Cardiology Authors: Tags: Cardiol J Source Type: research
More News: Atrial Fibrillation | Ischemic Stroke | Pharmaceuticals | Stroke | Vitamin K | Vitamins